---
title: Multitasking exercises improve arm strength
nct_id: NCT07536542
phase: NA
status: RECRUITING
sponsor: Ankara University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07536542"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07536542"
last_fetched: "2026-06-02T14:00:49.223Z"
source: "Parkinson's Pathways (curated)"
---
# Multitasking exercises improve arm strength

**Goal (in five words):** Multitasking exercises improve arm strength

**Official Title:** Effects of Dual-Task Training on Upper Extremity Function and Muscle Thickness in Parkinson's Disease

**Trial ID:** [NCT07536542](https://clinicaltrials.gov/study/NCT07536542)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Ankara University
- **Target Enrollment:** 38 participants
- **Start Date:** 2026-04-24
- **Completion Date:** 2026-07-24
- **Conditions:** Parkinson Disease (PD)
- **Interventions:** Dual-Task Training
- **Intervention Types:** BEHAVIORAL

## Summary For Families

The goal is to improve arm and hand function and increase muscle thickness in people with Parkinson's by reducing the drop in performance that happens when you try to move while also doing a thinking task. The approach is dual-task training, where repetitive upper-limb exercises are practiced at the same time as a cognitive or secondary motor task to retrain attention, timing, muscle activation, and strength; it is a non-drug rehabilitation method and does not directly interact with levodopa, and participants must have had no medication changes in the past 6 months. Participants should be aged 40 to 65 with idiopathic Parkinson's at Hoehn and Yahr stage 2 to 3, able to follow instructions (MoCA ≥21), and free of major upper limb injuries, atypical parkinsonism, severe sensory or psychiatric problems that would prevent regular participation.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 65 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist
* Modified Hoehn and Yahr stage 2 to 3
* No medication or dosage change within the last 6 months
* Cognitive capacity sufficient to understand and follow instructions, defined as Montreal Cognitive Assessment score ≥21
* Voluntary participation with written informed consent

Exclusion Criteria:

* Atypical or secondary parkinsonism
* Advanced orthopedic condition affecting the upper extremity
* Surgery, trauma, or immobilization involving the upper extremity within the last 6 months
* Wound or dermatological condition preventing upper extremity ultrasonographic evaluation
* Severe visual or hearing loss
* Severe depression, psychosis, or communication difficulty
* Any additional health problem preventing regular participation in the study
```

## Locations (1)

- Hacettepe University, Ankara, Turkey (Türkiye) _(39.9199, 32.8543)_
  - Ayla Fil, Assoc.Prof. PhD — (CONTACT) — +905074708330 — aylafil@gmail.com

## Central Contacts

- Büşra Seçkinoğulları Korkusuz, PhD — (CONTACT) — +905442436914 — bskorkusuz@ankara.edu.tr

---

*Canonical: https://parkinsonspathways.com/trial/NCT07536542*  
*HTML version: https://parkinsonspathways.com/trial/NCT07536542*  
*Source data: https://clinicaltrials.gov/study/NCT07536542*